TP53 and non-small cell lung carcinoma: Catherine Labbé’s group found dual TP53/EGFR mutations in 41% of 105 NSCLC patients; especially, missense mutation of TP53 resulted in reduced response rates and shortened OS with TKI therapy (Labbé et al., 2017).